For too long, regulatory teams have become bogged down by protracted reviews of the regulatory implications of each new product change, with potential risk to drug availability until these have been assessed and actions set in motion. Now Generative AI (GenAI) promises to change all that, say independent consultant Preeya Beczek and Agnes Cwienczek of ArisGlobal.
ogichobanov Shutterstock